BetterLife Pharma Inc.

C$0.20As of Sun 8 Nov 2026, 12:00 UTC

CSE:BETRHealthcare

Country Canada

PE (Fwd) —

TSR 9Y CAGR (42.28%)

Div yield —

ROE —

Biotechnology

Beta (5Y) 0.25

PE TTM —

TSR TTM 215.38%

Mkt cap C$126.7M

ROIC —

SE Grade™

—

Value

—

Quality

Moat

—

1Y Price

Reference

$0.221

—

7.80%

—

TTM

FYE 31 Jan CAD

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

◌—

Revenue$M

—

◌—

—

Revenue growth%

—

Gross margin%

—

Operating margin%

—

Net margin%

—

P/E ratio (avg)x

—

EV/EBITx

—

(6.26)

FCF yield (avg)%

—

(10.97)

(27.69)

(13.84)

(5.81)

—

(12.41)

—

FCF margin%

—

0.598

FCF / Net incomex

—

0.167

0.856

0.574

0.418

—

0.496

—

ROIC%

—

Return on equity%

—

(170.22)

Return on assets%

—

(12065.52)

(889.63)

(1564.83)

(680.07)

—

(1227.23)

—

(0.02)

EPS$

—

(0.10)

(0.03)

(0.01)

—

EPS growth%

—

74.62

(7.51)

63.93

—

63.93

—

(0.07)

Bookvalue per sh$

—

(0.12)

(0.10)

(0.09)

(0.07)

(0.08)

—

(0.01)

FCF per share$

—

(0.02)

—

Dividend per sh$

—

Div yield (avg)%

—

Payout ratio%

—

145.9

Shares (diluted)M

—

86.56

109.3

123.9

145.9

◌145.9

19.00%

—

Buyback yield%

—

(26.25)

(13.34)

(17.77)

◌—

(17.77)

—

(0.268)

D/E ratiox

—

(0.111)

(0.136)

(0.122)

(0.125)

(0.268)

(0.124)

—

32.83

Enterprise value$M

—

14.88

10.36

15.90

11.97

31.87

(7.01%)

—

0.026

LT debt$M

—

0.035

—

0.082

0.049

0.027

0.026

(5.83%)

—

Peers (US$92.16M)

Cap (US$)

enGene Therapeutics…

117.3M

—

Milestone Pharmaceutic…

107.5M

—

Eastwood Bio-Medical…

87.77M

—

Retension Pharmaceutic…

91.98M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(12.60)

(38.93)

Own earn%

—

Sh yield%

—

(17.77)

Owners

Insiders/Inst%

8.94

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

—

EPS growth years

2/3

Dividend streakyrs

Op margin range%

—

$1 testx

—

Incr. ROIC%

—

BetterLife Pharma Inc., a biotechnology company, engages in the development of psychedelic-derived compounds. It focuses on developing and commercializing BETR-001, a non-hallucinogenic and non-controlled LSD derivative to treat neuro-psychiatric and neurological disorders.

Revenue by segment

No breakdown available

Asset mix

Trend

Other

94.28%

Cash and investments

5.72%

Reinvestment returns

No breakdown available